Table 1.

Demographic and clinical characteristics of patients with carbapenem-resistant Acinetobacter baumannii (CRAB) bacteremia treated with colistin vs. colistin plus meropenem.

Patient characteristics	Colistin (n = 40)	Colistin plus meropenem (n = 31)	p
Age, years	64.57 ± 16.24	70.06 ± 12.01	0.12
Sex, male	22 (55.0%)	20 (64.5%)	0.41
Comorbid condition
Diabetes mellitus	16 (40.0%)	12 (38.7%)	1.00
Cardiovascular disease	8 (20.0%)	9 (29.0%)	0.37
Chronic lung disease	11 (27.5%)	9 (29.0%)	0.88
Renal impairment	12 (30.0%)	10 (32.3%)	0.83
Chronic liver disease	8 (20.0%)	3 (9.7%)	0.32
Cerebrovascular disease	17 (42.5%)	13 (41.9%)	0.96
Malignancy	6 (15.0%)	9 (29.0%)	0.15
Charlson Comorbidity Index	3.20 ± 1.77	3.32 ± 1.44	0.75
Pitt bacteremia score	4.05 ± 2.51	3.93 ± 2.30	0.84
Steroid/immunosuppressant use	5 (12.5%)	8 (25.8%)	0.15
Recent surgery	11 (27.5%)	10 (32.3%)	0.66
CVC	36 (90.0%)	28 (90.3%)	0.96
Type of infection
Pneumonia	15 (37.5)	16 (51.6)	0.33
CRI	17 (42.5%)	10 (32.3)	0.46
SSTI	4 (10.0)	3 (9.7)	1.00
IAI	2 (5.0)	1 (3.2)	1.00
UTI	0 (0)	1 (3.2)	0.43
PB	1 (2.5)	0 (0)	1.00
CNS infection	1(2.5)	0 (0)	1.00
ABs before colistin administration	15 (37.5)	5 (16.1)	0.06
ABs during colistin and/or meropenem administration	8 (20.0)	3 (9.7)	0.32

Data are presented as mean ± standard deviation, SD for continuous variables and as n (%) of patient s for categorical variables. CVC, central venous catheter; CRI, central line associated infection; UTI, urinary tract infection; SSTI, skin and soft tissue infection; IAI, intra-abdominal infection; PB, primary bacteremia; CNS, central nervous system, ABs, antibiotics other than colistin or meropenem.